{"id":1702,"date":"2026-10-06T12:48:51","date_gmt":"2026-10-06T12:48:51","guid":{"rendered":"https:\/\/dev.ich.org\/index.php\/guidelines\/s8\/"},"modified":"2026-10-06T12:48:51","modified_gmt":"2026-10-06T12:48:51","slug":"s8","status":"publish","type":"guideline","link":"https:\/\/dev.ich.org\/index.php\/guidelines\/s8\/","title":{"rendered":"S8 \u2013 Immunotoxicity Studies for Human Pharmaceuticals"},"content":{"rendered":"<p>The ICH Harmonised Guideline was adopted under <em>Step 4 <\/em>in September 2005. This Guideline provides recommendations on nonclinical testing approaches to identify compounds which have the potential to be immunotoxic, and guidance on a weight-of-evidence decision making approach for immunotoxicity testing It applies to new pharmaceuticals intended for use in humans, as well as to marketed pharmaceuticals proposed for different indications or other variations on the current product label in which the change could result in unaddressed and relevant immunotoxicity issues.<\/p>\n<p>In addition, the Guideline might also apply to drugs in which clinical signs of immunotoxicity are observed during clinical trials and following approval to market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The ICH Harmonised Guideline was adopted under Step 4 in September 2005. This Guideline provides recommendations on nonclinical testing approaches to identify compounds which have the potential to be immunotoxic, and\u2026<\/p>\n","protected":false},"featured_media":0,"template":"","guideline_category":[19],"guideline_tag":[],"rd_phase":[],"class_list":["post-1702","guideline","type-guideline","status-publish","hentry","guideline_category-safety"],"acf":[],"_links":{"self":[{"href":"https:\/\/dev.ich.org\/index.php\/wp-json\/wp\/v2\/guideline\/1702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.ich.org\/index.php\/wp-json\/wp\/v2\/guideline"}],"about":[{"href":"https:\/\/dev.ich.org\/index.php\/wp-json\/wp\/v2\/types\/guideline"}],"version-history":[{"count":0,"href":"https:\/\/dev.ich.org\/index.php\/wp-json\/wp\/v2\/guideline\/1702\/revisions"}],"wp:attachment":[{"href":"https:\/\/dev.ich.org\/index.php\/wp-json\/wp\/v2\/media?parent=1702"}],"wp:term":[{"taxonomy":"guideline_category","embeddable":true,"href":"https:\/\/dev.ich.org\/index.php\/wp-json\/wp\/v2\/guideline_category?post=1702"},{"taxonomy":"guideline_tag","embeddable":true,"href":"https:\/\/dev.ich.org\/index.php\/wp-json\/wp\/v2\/guideline_tag?post=1702"},{"taxonomy":"rd_phase","embeddable":true,"href":"https:\/\/dev.ich.org\/index.php\/wp-json\/wp\/v2\/rd_phase?post=1702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}